Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 326-350 of 2,022
Active Not RecruitingNCT06791122

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

This study is looking at gather new information on CT-155 for people with Schizophrenia. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
RecruitingNCT05945602

Neurophysiologic Biomarkers for Cognitive Rehabilitation

This observational study is following people with Schizophrenia Spectrum Disorders to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 18 Years to 75 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
RecruitingNCT03817502

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

This study is looking at evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
Bulgaria, Colombia, Mexico, Romania, Russian Federation, Serbia, Ukraine, United States
Sponsor
Gedeon Richter Plc.
Condition
Schizophrenia
RecruitingNCT06336382

Tau Biomarkers in Late-onset Psychosis (LOP)

This study is looking at confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing for people with Late Onset Schizophrenia or Delusional Disorder. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 65 Years to 85 Years
Countries
United States
Sponsor
Jeremy Koppel
Condition
Schizophrenia
RecruitingNCT05958875

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

This study is looking at whether a digital support tool can help people with Schizophrenia and Related Disorders or Early Treatment-Resistance. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Austria, Germany, Italy, Spain, United Kingdom
Sponsor
Dr. Inge Winter
Condition
Schizophrenia
RecruitingNCT05389787

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

This study is looking at investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients for people with Schizophrenia, Cerebellar Function, or Condition. Some participants may receive Sham instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Northwell Health
Condition
Schizophrenia
RecruitingNCT06191965

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

This observational study is following people with Schizophrenia and Related Disorders, Mitochondrial Alteration, or Cognitive Impairment to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
Switzerland, United States
Sponsor
Mclean Hospital
Condition
Schizophrenia
RecruitingNCT07192042

Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizophrenia

This observational study is following people with Schizophrenia and Schizophrenia Spectrum Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 20 Years to 70 Years
Countries
Taiwan
Sponsor
Taipei Medical University Shuang Ho Hospital
Condition
Schizophrenia
RecruitingNCT05435300

Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia

This study is looking at examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia for people with Schizophrenia or Schizoaffective. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherOver 18 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia
Not Yet RecruitingNCT03575000

Bromocriptine for Patients With Schizophrenia and Prediabetes

This study is looking at be a small, short-duration pilot focusing on safety and tolerability for people with Schizophrenia or PreDiabetes. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
VA Pittsburgh Healthcare System
Condition
Schizophrenia
Active Not RecruitingNCT04318977

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia

This study is looking at care and outcomes for people with Negative Symptoms With Primary psychosis or Schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 75 Years
Countries
Czech Republic, Germany
Sponsor
University of Regensburg
Condition
Schizophrenia
RecruitingNCT05299749

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

This study is comparing stg-rt-fMRI-Neurofeeback with sham-rt-fMRI for people with Schizophrenia, Auditory Hallucination, or Treatment-resistant Schizophrenia. Participants receive stg-rt-fMRI-Neurofeeback or sham-rt-fMRI and complete study visits and assessments.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Boston VA Research Institute, Inc.
Condition
Schizophrenia
RecruitingNCT07122895

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

This study is looking at examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 20 Years to 65 Years
Countries
Taiwan
Sponsor
China Medical University Hospital
Condition
Schizophrenia
Not Yet RecruitingNCT07146802

Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial

This study is looking at compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis for people with Schizophrenia Spectrum Disorder. Participants take part in psychoeducation and complete follow-up assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Global
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
Not Yet RecruitingNCT07152184

Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

This study is looking at whether a digital support tool can help people with With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, or Schizophrenia Spectrum and Other psychosis. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
Global
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia